Literature DB >> 18240348

H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium.

Hyung Wook Kim1, Gwang Ha Kim, Jong Yun Cheong, Ung Suk Yang, Seung Keun Park, Chul Soo Song, Dae Hwan Kang, Geun Am Song.   

Abstract

AIM: To investigate whether adding ecabet sodium to the standard triple therapy for H pylori infection improve eradication rate.
METHODS: Two hundred and fifty-seven H pylori-infected patients were randomly assigned to standard triple therapy (group A, n = 129) or triple therapy plus ecabet sodium (group B, n = 128). Successful eradication was defined as a negative (13)C-urea breath test 6-8 wk after completion of treatment.
RESULTS: After completion of therapy, 194/257 patients showed negative (13)C-urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B (P = 0.204). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B (P = 0.044). There were no significant differences in the side effects experienced by the patients in the two treatment groups.
CONCLUSION: Our results suggest that the addition of ecabet sodium improves the efficacy of the standard triple therapy for H pylori.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240348      PMCID: PMC2687058          DOI: 10.3748/wjg.14.908

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  [Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care].

Authors:  F Gomollón; J Valdepérez; R Garuz; J Fuentes; F Barrera; J Malo; M Tirado; M A Simón
Journal:  Med Clin (Barc)       Date:  2000-06-03       Impact factor: 1.725

2.  Effects of the new anti-ulcer agent 12-sulfodehydroabietic acid monosodium salt on duodenal alkaline secretion in rats.

Authors:  Y Onoda; T Magaribuchi; H Tamaki
Journal:  Arzneimittelforschung       Date:  1990-05

3.  Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.

Authors:  Y Fukuda; I Yamamoto; M Okui; Y Tonokatsu; T Shimoyama
Journal:  J Clin Gastroenterol       Date:  1995       Impact factor: 3.062

Review 4.  Eradication of Helicobacter pylori infection.

Authors:  R H Hunt
Journal:  Am J Med       Date:  1996-05-20       Impact factor: 4.965

5.  Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.

Authors:  M Vergara; M Vallve; J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

Review 6.  Therapy of Helicobacter pylori.

Authors:  Ramona McLoughlin; Istvan Racz; Martin Buckley; Humphrey J O'Connor; Colm O'Morain
Journal:  Helicobacter       Date:  2004       Impact factor: 5.753

7.  Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a- octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1- phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach.

Authors:  Y Ito; Y Sugawara; O Takaiti; S Nakamura
Journal:  J Pharmacobiodyn       Date:  1991-09

8.  Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions.

Authors:  K Shibata; Y Ito; A Hongo; A Yasoshima; T Endo; M Ohashi
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

9.  Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.

Authors:  S Bruley des Varannes; P Levy; S Lartigue; F Dellatolas; M Lemaire; J P Galmiche
Journal:  Aliment Pharmacol Ther       Date:  1994-06       Impact factor: 8.171

10.  Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.

Authors:  Engin Altintas; Orhan Sezgin; Oguz Ulu; Ozlem Aydin; Handan Camdeviren
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

View more
  4 in total

1.  Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.

Authors:  Makoto Sasaki; Naotaka Ogasawara; Keiko Utsumi; Naohiko Kawamura; Tskeshi Kamiya; Hiromi Kataoka; Satoshi Tanida; Tsutomu Mizoshita; Kunio Kasugai; Takashi Joh
Journal:  J Clin Biochem Nutr       Date:  2010-06-17       Impact factor: 3.114

2.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

Review 3.  Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Gut Liver       Date:  2021-03-15       Impact factor: 4.519

4.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.